Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease.

Shiran UdiLiad HindenMajdoleen AhmadAdi DroriMalliga R IyerResat CinarMichal Herman-EdelsteinJoseph Tam

Published in: British journal of pharmacology (2019)

Collectively, our results highlight the therapeutic relevance of blocking CB1 receptors and iNOS in ameliorating obesity-induced CKD.

Keyphrases